Jiangsu Kangyuan Pharma and Shengpu Zetai Achieve Milestone: AI-Powered KYS2301 Gel Successfully Submits IND Application

As a traditional pharmaceutical company with the modernization of Chinese medicine at its core, Kanion Pharmaceutical's collaboration with AI pharmaceutical enterprise Space Peptides has successfully achieved an important transformation towards intelligent innovation for traditional pharmaceutical companies. As the world's first CCR8 peptide inhibitor,KYS2301 Gel Rapidly and Precisely Discovers New Drug Molecules Through AI Technology, Taking Only 4 Months from Target Discovery to PCC (Preclinical Candidate Compound) Acceptance, taking only 18 months to reach the IND application stage, which is more than 60% shorter than the traditional R&D cycle, marking a significant breakthrough in the company's First-in-Class innovative drug pipeline. Notably, this project successfully overcame the technical challenge of transdermal absorption for peptides with a molecular weight exceeding 2000, providing an important reference for the subsequent development of peptide-based drugs.

Atopic Dermatitis (Atopic Dermatitis (AD) is a chronic inflammatory skin disease, often characterized by recurrent eczematous lesions (i.e., poorly demarcated, erythematous (red) plaques, with early exudation, blistering and crusting, and later scaling, fissuring, and lichenification (thickening)), intense pruritus, and discomfort. AD is associated with varying degrees of lesion severity and imposes a broad symptom burden, including pruritus, skin pain, sleep disturbances, and mental health disorders, negatively impacting quality of life. Current treatment options include topical medications (e.g., corticosteroids, calcineurin inhibitors), oral immunosuppressants (e.g., JAK inhibitors), and biologics (e.g., dupilumab), but existing therapies still present issues such as insufficient efficacy, safety risks, or inconvenient administration.

KYS2301 Gel, as the world's first CCR8 peptide inhibitor, demonstrates significant advantages through the precise optimization of molecular structure using AI technology:

Excellent Safety:Peptide drugs have low immunogenicity, high stability, can replace hormones, and local topical administration can avoid systemic adverse reactions;

Patient-Friendly Design:Gel formulations are convenient for patients to apply autonomously, especially suitable for children, the elderly, and those with difficulties in oral administration, significantly improving treatment compliance.

The rapid development of KYS2301 gel is attributed to Space Peptides' AI drug discovery platform. By utilizing deep learning algorithms to analyze vast amounts of compound data, the platform completed the screening and optimization of active molecules in just one-third of the time required by traditional research and development methods, significantly shortening the preclinical research cycle. The Investigational New Drug (IND) application for KYS2301 gel (a CCR8 peptide inhibitor), an innovative drug project developed based on AI technology, has officially been approved by the Center for Drug Evaluation (CDE) under China's National Medical Products Administration (NMPA). This approval validates the core value of AI technology in drug design, toxicity prediction, and formulation optimization, offering a replicable innovation model for the industry.

Technological Leadership:The world's first targetedTopical Peptide Inhibitor of CCR8: AI-Driven Molecular Design Achieves Dual Breakthrough in "High Activity + Low Toxicity"

Clinical Needs Orientation:Covering Moderate to SevereAD patient population, especially addressing the unmet treatment needs of children and special populations;

Industrialization Potential:The production process of gel dosage forms is mature, with controllable costs, and it is expected to become a promising option in the future.First-line therapy for AD.